Sally Paredes
Research Subjects
Sally Paredes has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Brady Ernesto Beltran
Servicio de Oncología Médica, Hospital Edgardo Rebagliati Martins, Instituto de Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú
7 shared publications - Denisse Castro
Centro de Investigación de Medicina de Precisión, Hospital Nacional Edgardo Rebagliati Martins, Universidad San Martín de Porres, Lima, Peru
4 shared publications - Jorge J. Castillo
Bing Center for Waldenstrom's Macroglobulinemia Dana‐Farber Cancer Institute Boston MA USA
3 shared publications - Camila Peña
Hospital del Salvador, Santiago, Chile
2 shared publications - David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
2 shared publications Eduardo M. Sotomayor
George Washington Cancer Center, George Washington University, Washington, DC
2 shared publications
Latest Publications
- Open Access
- 8 June 2023
- Published by Sociedad Peruana de Oncología Médica del Perú in ONKORESEARCH
- Vol. 2 (1) , 26-33
Neutrophil-to-lymphocyte Ratio as a PrognosticBiomarker in Peruvian Patients with AcralMelanoma
Objective. Our aim was to evaluate whether NLR, LMR, and PLR serve as prognostic biomarkers in AM, the most frequent subtype of cutaneous melanoma (CM) in Peru. Materials and methods. A retrospective study was conducted, including patients diagnosed with AM between 2010 and 2015. Survival analysis was performed using Kaplan-Meier curves and comparisons were made using the log-rank test. Univariate and multivariate survival models were constructed usingCox regression analysis. A p-value less than 0.05 was considered significant. Results. Among our cohort of 135 patients with CM, 51.1% (69 cases) had AM. The median age was 68 years, with a predominance of females (55%), and 88.4% had the plantar site as the primary site. The 5-year overall survival (OS) rate was 54.3%. In the univariate analysis, Clark level III/IV, anaplasia, lymphocytic invasion, stage III-IV, and NLR were associated with poor prognosis. In multivariateanalysis, NLR >3.5 (HR 3.9, 95% CI 1.5-10.3, p=0.005) and Clark level III-IV (HR 3.5, 95% CI 1.6- 7.8, p=0.002) were associated with poor OS. Conclusion. NLR emerges as an independent prognostic factor for OS among Peruvian patients with AM in a single cancer center institution.
- 8 June 2023
- Published by Sociedad Peruana de Oncología Médica del Perú in ONKORESEARCH
- Vol. 2 (1) , 26-33
Open AccessNeutrophil-to-lymphocyte Ratio as a PrognosticBiomarker in Peruvian Patients with AcralMelanoma
Objective. Our aim was to evaluate whether NLR, LMR, and PLR serve as prognostic biomarkers in AM, the most frequent subtype of cutaneous melanoma (CM) in Peru. Materials and methods. A retrospective study was conducted, including patients diagnosed with AM between 2010 and 2015. Survival analysis was performed using Kaplan-Meier curves and comparisons were made using the log-rank test. Univariate and multivariate survival models were constructed usingCox regression analysis. A p-value less than 0.05 was considered significant. Results. Among our cohort of 135 patients with CM, 51.1% (69 cases) had AM. The median age was 68 years, with a predominance of females (55%), and 88.4% had the plantar site as the primary site. The 5-year overall survival (OS) rate was 54.3%. In the univariate analysis, Clark level III/IV, anaplasia, lymphocytic invasion, stage III-IV, and NLR were associated with poor prognosis. In multivariateanalysis, NLR >3.5 (HR 3.9, 95% CI 1.5-10.3, p=0.005) and Clark level III-IV (HR 3.5, 95% CI 1.6- 7.8, p=0.002) were associated with poor OS. Conclusion. NLR emerges as an independent prognostic factor for OS among Peruvian patients with AM in a single cancer center institution.
- 3 May 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (7) , 1225-1233
The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study
Readily accessible biomarkers for risk stratification in settings with limited resources are lacking. We evaluated the effect of high red distribution width-coefficient of variation (RDW-CV) values (>14%) on all-cause and lymphoma-specific mortality outcomes among 118 patients with peripheral T-cell lymphoma (PTCL) who received systemic treatment at two tertiary centers between 2010 and 2019. With a median follow-up of 45 months, patients with a high RDW-CV had a lower 4-year overall survival rate (34% vs. 45%, p = 0.015) and higher cumulative incidence of lymphoma mortality (54% vs. 34%, p = 0.007). RDW-CV >14% was associated with all-cause (adjusted Hazard Ratio [aHR] 1.98, 95% confidence interval [CI] 1.10–3.56) and lymphoma-specific mortality (aHR 2.64, 95% CI 1.32–5.29). In our study, RDW-CV emerges as an easily accessible and complementary prognostic biomarker for risk stratification among treated patients with de novo PTCL. Further research should validate the predictive role of RDW-CV in prospective cohorts.
- 3 May 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (7) , 1225-1233
The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study
Readily accessible biomarkers for risk stratification in settings with limited resources are lacking. We evaluated the effect of high red distribution width-coefficient of variation (RDW-CV) values (>14%) on all-cause and lymphoma-specific mortality outcomes among 118 patients with peripheral T-cell lymphoma (PTCL) who received systemic treatment at two tertiary centers between 2010 and 2019. With a median follow-up of 45 months, patients with a high RDW-CV had a lower 4-year overall survival rate (34% vs. 45%, p = 0.015) and higher cumulative incidence of lymphoma mortality (54% vs. 34%, p = 0.007). RDW-CV >14% was associated with all-cause (adjusted Hazard Ratio [aHR] 1.98, 95% confidence interval [CI] 1.10–3.56) and lymphoma-specific mortality (aHR 2.64, 95% CI 1.32–5.29). In our study, RDW-CV emerges as an easily accessible and complementary prognostic biomarker for risk stratification among treated patients with de novo PTCL. Further research should validate the predictive role of RDW-CV in prospective cohorts.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6708-6710
Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Introduction. There are different biological variables associated to overall survival (OS) in Diffuse Large B-cell lymphoma (DLBCL). Anemia (Adams HJ et al 2015
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6708-6710
Open AccessValidating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Introduction. There are different biological variables associated to overall survival (OS) in Diffuse Large B-cell lymphoma (DLBCL). Anemia (Adams HJ et al 2015
- Open Access
- 26 March 2021
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 38 (1) , 178-9
Teleonconsultas en oncología: experiencia en un hospital del Perú durante la pandemia
- 26 March 2021
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 38 (1) , 178-9
Open AccessTeleonconsultas en oncología: experiencia en un hospital del Perú durante la pandemia
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 25-27
Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)
Introduction. There are different scoring systems to differentiate risk groups in patients with DLBCL treated with chemoimmunotherapy. Those systems have used the same 5 variables (age, performance status, LDH, stage, extranodal involvement) for 27 years. However, LATAM data have not been included in the development of previous scoring systems. It is important to mention that novel biological variables, such as albumin, beta-2-microglobulin (B2M) and platelet/lymphocyte ratio (PLR), have been reported and could improve discrimination (Villela et al. Blood 2019; 134Suppl_1: 1613). Therefore, we carried out a large, multinational study to develop and validate a LATAM-IPI score. Methods. This is a retrospective cohort of 1030 patients with a diagnosis of DLBCL treated with standard chemoimmunotherapy with curative intent between 2010 and 2018. Data were obtained from 8 LATAM countries: Argentina, Colombia, Chile, Guatemala, Mexico, Paraguay, Peru, and Venezuela. The five classic IPI variables (age, ECOG, extranodal involvement, LDH, stage) were analyzed and albumin and PLR were added (Villela et al. Blood 2019; 134Suppl_1: 1613). B2M was not included because it was not requested regularly in all countries. Development of LATAM-IPI: The training set consisted of 85% of the sample, randomly selected, and the remaining 15% was reserved for internal validation. Using the training set, the univariate and multivariate association between clinical prognostic factors and OS was analyzed fitting Cox proportional-hazard models. Outcomes. Clinical characteristics of the training (n=878) and internal validation (n=151) cohorts are shown in Table 1. There were no statistical differences in baseline characteristics between the cohorts. The median follow-up for the whole cohort was 36 months (IQR: 11-57). When exploring the classic IPI variables on the training set, all variables were associated with high risk of mortality [age 65-74, Hazard Ratio (HR) 1.24, 95% CI 0.96 to 1.58, p=0.08; age ≥75, HR 1.71, 95% CI 1.28 to 2.28, p=0.0003), ECOG (≥ 2, HR=2, 95% CI 1.61 to 2.53; pmultivariate analysis. The independent variables were albumin (LDH (ratio 1.1 to 2.9, HR 1.30, 95% CI 1.02 to 1.67, p=0.03, 1 point; ratio ≥3, HR=1.84, 95% CI 1.31 to 2.5, p=0.0004, 2 points), advanced stage (HR 1.65, 95% CI 1.27 to 2.13, p=0.0001, 1 point), age (≥75, HR= 1.51, 95% CI 1.15 to 1.98, p=0.003, 1 point), and ECOG (≥2, HR 1.40, 95% CI 1.10 to 1.77, p=0.005). Now, for the development of LATAM-IPI, the groups were distributed as follows: 0 points, low; 1-3 points, intermediate; 4-6 points, high risk. There were no differences in the distribution of the risk groups between training and validation sets (Table 2). In the learning cohort, the 5-year OS rates for low, intermediate and high risk were 81%, 63% and 33%, respectively (pFigure 1). Conclusions: Using multinational learning and validation cohorts including over 1,000 DLBCL patients treated with standard chemoimmunotherapy in LATAM, we developed a novel LATAM-IPI score using age ≥75 years, ECOG ≥2, advanced stage, LDH ratio (1.1-29 and ≥3) and albumin <3.5 mg/dl. Next steps are to disseminate our results with other involved researchers in LATAM to prospectively assess and reproduce our results. We expect this score will help to further define the prognosis of DLBCL patients in LATAM.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 25-27
Open AccessProposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)
Introduction. There are different scoring systems to differentiate risk groups in patients with DLBCL treated with chemoimmunotherapy. Those systems have used the same 5 variables (age, performance status, LDH, stage, extranodal involvement) for 27 years. However, LATAM data have not been included in the development of previous scoring systems. It is important to mention that novel biological variables, such as albumin, beta-2-microglobulin (B2M) and platelet/lymphocyte ratio (PLR), have been reported and could improve discrimination (Villela et al. Blood 2019; 134Suppl_1: 1613). Therefore, we carried out a large, multinational study to develop and validate a LATAM-IPI score. Methods. This is a retrospective cohort of 1030 patients with a diagnosis of DLBCL treated with standard chemoimmunotherapy with curative intent between 2010 and 2018. Data were obtained from 8 LATAM countries: Argentina, Colombia, Chile, Guatemala, Mexico, Paraguay, Peru, and Venezuela. The five classic IPI variables (age, ECOG, extranodal involvement, LDH, stage) were analyzed and albumin and PLR were added (Villela et al. Blood 2019; 134Suppl_1: 1613). B2M was not included because it was not requested regularly in all countries. Development of LATAM-IPI: The training set consisted of 85% of the sample, randomly selected, and the remaining 15% was reserved for internal validation. Using the training set, the univariate and multivariate association between clinical prognostic factors and OS was analyzed fitting Cox proportional-hazard models. Outcomes. Clinical characteristics of the training (n=878) and internal validation (n=151) cohorts are shown in Table 1. There were no statistical differences in baseline characteristics between the cohorts. The median follow-up for the whole cohort was 36 months (IQR: 11-57). When exploring the classic IPI variables on the training set, all variables were associated with high risk of mortality [age 65-74, Hazard Ratio (HR) 1.24, 95% CI 0.96 to 1.58, p=0.08; age ≥75, HR 1.71, 95% CI 1.28 to 2.28, p=0.0003), ECOG (≥ 2, HR=2, 95% CI 1.61 to 2.53; pmultivariate analysis. The independent variables were albumin (LDH (ratio 1.1 to 2.9, HR 1.30, 95% CI 1.02 to 1.67, p=0.03, 1 point; ratio ≥3, HR=1.84, 95% CI 1.31 to 2.5, p=0.0004, 2 points), advanced stage (HR 1.65, 95% CI 1.27 to 2.13, p=0.0001, 1 point), age (≥75, HR= 1.51, 95% CI 1.15 to 1.98, p=0.003, 1 point), and ECOG (≥2, HR 1.40, 95% CI 1.10 to 1.77, p=0.005). Now, for the development of LATAM-IPI, the groups were distributed as follows: 0 points, low; 1-3 points, intermediate; 4-6 points, high risk. There were no differences in the distribution of the risk groups between training and validation sets (Table 2). In the learning cohort, the 5-year OS rates for low, intermediate and high risk were 81%, 63% and 33%, respectively (pFigure 1). Conclusions: Using multinational learning and validation cohorts including over 1,000 DLBCL patients treated with standard chemoimmunotherapy in LATAM, we developed a novel LATAM-IPI score using age ≥75 years, ECOG ≥2, advanced stage, LDH ratio (1.1-29 and ≥3) and albumin <3.5 mg/dl. Next steps are to disseminate our results with other involved researchers in LATAM to prospectively assess and reproduce our results. We expect this score will help to further define the prognosis of DLBCL patients in LATAM.
- 1 September 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (9) , e551-e557
High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy
- 1 September 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (9) , e551-e557
High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy
- 1 April 2018
- Published by Elsevier in Leukemia Research
- Vol. 67, 82-85
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma
- 1 April 2018
- Published by Elsevier in Leukemia Research
- Vol. 67, 82-85
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma